Stockscreener 앱 받기
24.40
3.53%
0.91
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics Advances in Rare Skin Disease Therapies - TipRanks
A great week for institutional investors who own 26% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) - simplywall.st
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MyChesCo
Palvella Therapeutics Strengthens Executive Leadership Team - GlobeNewswire
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer - Investing.com
Palvella Therapeutics hires Ashley Kline as Chief Commercial Officer By Investing.com - Investing.com India
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - The Manila Times
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease ... - Eagle-Tribune
Palvella Taps Rare Disease Star Who Led $500M Oxervate Launch for Upcoming Genetic Disease Treatment - Stock Titan
Brokers Set Expectations for PVLA FY2025 Earnings - Defense World
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Canaccord Genuity Group Has Lowered Expectations for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Analysts Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43 - Defense World
Palvella Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Palvella Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Palvella Therapeutics reports Q1 2025 loss, stock dips - Investing.com Nigeria
Palvella Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Palvella Therapeutics Reports Strong Q1 Financial Results - TipRanks
PALVELLA THERAPEUTICS Earnings Results: $PVLA Reports Quarterly Earnings - Nasdaq
PALVELLA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Palvella's Breakthrough Skin Disease Treatment Hits Major Milestone as Phase 3 Trial Surpasses Target - Stock Titan
Palvella Therapeutics (PVLA) Projected to Post Quarterly Earnings on Thursday - Defense World
Palvella Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Palvella Therapeutics Rings the Opening Bell - Nasdaq
Palvella Therapeutics to Ring Nasdaq Opening Bell - MyChesCo
Palvella Therapeutics to Host First Quarter 2025 Financial - GlobeNewswire
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 - The Manila Times
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update ... - Bluefield Daily Telegraph
Renaissance Technologies LLC Buys New Holdings in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 - GlobeNewswire
Leading Rare Skin Disease Biotech Palvella Makes Nasdaq Debut with Opening Bell Ceremony - Stock Titan
Geode Capital Management LLC Invests $171,000 in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 - StreetInsider
Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025 - Yahoo Finance
Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference - MyChesCo
One Palvella Therapeutics Insider Raised Their Stake In The Previous Year - Yahoo Finance
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
1.30%
3.35%
자본화:
|
볼륨(24시간):